Governance and RemunerationCorporate Governance ReportExecutive Committee
4Executive Committee
Through our Organizational Regulations, the Board of Directors has delegated the responsibility and authority necessary or appropriate to carry out the day-to-day and operational activities of PolyPeptide to the Executive Committee under the leadership of the CEO.
The CEO is accountable for the sustainable management and results-oriented performance of the Group. As such, the CEO leads, manages, supervises and coordinates the Executive Committee and the Extended Group Management15 as well as realizes the corporate goals and strategy as set by the Board of Directors. The detailed responsibilities and functions of the Executive Committee, including the CEO and the CFO, are described in section 6 of the Organizational Regulations.
In general, meetings of the Executive Committee take place on bi-weekly or monthly basis as determined by the CEO, with the expectation that there would be no fewer than six such meetings per calendar year (as provided for in the Organizational Regulations). The resolutions of the Executive Committee are taken by the majority of the members of the Executive Committee present, where the CEO has the power to overrule any Executive Committee resolution. At each meeting the CFO presents the financial situation of the Group to-date, followed by a discussion on other non-financial pre-determined agenda items covering a range of topics across all relevant business and operational areas.
4.1Members of the Executive Committee
As of 31 December 2021, the Executive Committee comprised the CEO, the CFO, the Director of Global Sales and Marketing, the Director of Global Operations and the General Counsel. In addition, Jane Salik (the Group's former CEO up and until the First Day of Trading) was a member of the Executive Committee until 17 August 2021 (see section 3.1 “Members of the Board of Directors” of this Corporate Governance Report). The year of appointment in the table below reflects each Executive Committee member’s respective appointment in his/her position with the Group (including at Group subsidiaries).
1Member of the Executive Committee as CEO-elect as of 1 April 2021 and CEO as of 29 April 2021.
2Member of the Executive Committee and Director of Global Sales and Marketing until 31 December 2021. Since 1 January 2022, Mr. Christensen is supporting selected business development projects until his retirement towards the end of 2022.
3Member of the Executive Committee as of 1 September 2021.
4Member of the Executive Committee and Director Global Sales and Marketing as of 1 January 2022.
15As of 1 January 2022 the Extended Group Management has been restructured as the PolyPeptide Management Committee. The PolyPeptide Management Committee consists of the Executive Committee together with Director Global Innovation & Technology, Chief Human Resources Officer (new position for H1 2022), Director Global Quality, Director Global Development / Regulatory / IP and Head of Investor Relations and Corporate Communications.
Set out below is a short description of each Executive Committee member's business experience, education and activities.
Raymond De Vré
Chief Executive Officer
Nationality:Belgian
Year of birth:1968
Professional background
Functions at PolyPeptide
Chief Executive Officer (since 2021)
Chairman / Director of several PolyPeptide subsidiaries (since 2021)
Outside mandates at listed / non-listed companies or non-profit organizations
None
Former outside activities and functions
Senior Vice President, Head of Biologics and member of the Management Committee, Dr. Reddy's Laboratories, Switzerland (2018–2021)
Senior Vice President Global Business Operations and Strategy, Biologics, Dr. Reddy's Laboratories, Switzerland (2017–2018)
Vice President Commercial, Biologics, Dr. Reddy's Laboratories, Switzerland (2012–2017)
Associate, Latham & Watkins LLP, United Kingdom (2008–2012)
Education
Juris Doctor, James Kent Scholar, Columbia Law School, USA (2008)
Bachelor of Arts, summa cum laude, University of Florida, USA (2000)
Read More
Neil James Thompson
Director Global Sales and Marketing
Nationality:British
Year of birth:1972
Professional background
Functions at PolyPeptide
Director Global Sales and Marketing (as of 1 January 2022)
Group Commercial Director (2019–2022)
Director Business Development Europe (2015–2019)
Associate Director Business Development Europe (2010–2015)
Business Manager Custom Development (2006–2010)
Regional Sales Manager (2004–2005)
Outside mandates at listed / non-listed companies or non-profit organizations
Member of the EuroPeptides Advisory Board for the EuroPeptides/EuroTIDES event (since 2012) (event managed and ran by Informa PLC – listed company)
Former outside activities and functions
Peptide Product Manager, Bachem (UK) Ltd, United Kingdom (2001–2003)
Assistant Production Manager, Bachem (UK) Ltd, United Kingdom (1999–2003)
Assistant Production Manager, Peninsula Laboratories (Europe) Ltd, United Kingdom (1993–1999)
Education
Bachelor of Science in Applied Chemistry and Biochemistry, Liverpool John Moores University, England (1997)
Read More
In 2021, the Executive Committee, under the leadership of the CEO, was further supported by additional members of management, that, together with the Executive Committee, formed the Extended Group Management16.
16As of 1 January 2022 the Extended Group Management has been restructured as the PolyPeptide Management Committee. The PolyPeptide Management Committee consists of the Executive Committee together with Director Global Innovation & Technology, Chief Human Resources Officer (new position for H1 2022), Director Global Quality, Director Global Development / Regulatory / IP and Head of Investor Relations and Corporate Communications.
4.2Other activities and vested interests
Except as disclosed in the biographies of the members of the Executive Committee, no further activities or vested interests are carried out outside of PolyPeptide.
4.3Mandates and other permitted activities
Pursuant to art. 23 of the Articles of Association, with the approval of the Board of Directors, the members of the Executive Committee may have the following other functions in the superior management or administrative bodies of legal entities obliged to register themselves in a Swiss commercial register or a foreign equivalent thereof:
up to one (1) mandate as member of the board of directors or any other superior management or administrative body of listed companies; and, in addition
up to five (5) mandates as member of the board of directors or any other superior management or administrative body of other legal entities that do not meet the above mentioned criteria.
With respect to the additional activities of the members of the Executive Committee, mandates in companies that are under uniform control or the same beneficial ownership are deemed to be one mandate.
mandates in companies which are controlled by the Company or which control the Company;
mandates held at the request of the Company or companies controlled by it; no member of the Executive Committee shall, however, hold more than ten (10) such mandates; and
mandates in associations, charitable organizations, foundations, employee welfare foundations and other similar organizations; no member of the Executive Committee shall, however, hold more than fifteen (15) such mandates.
4.4Management contracts
The Company and its subsidiaries have not entered into any management contracts with third parties.